Representations of IC. IC hereby represents to Collaborator that: 9.1.1 IC has the requisite power and authority to enter into this CRADA and to perform according to its terms, and that IC’s official signing this CRADA has authority to do so. 9.1.2 To the best of its knowledge and belief, neither IC nor any of its personnel involved in this CRADA is presently subject to debarment or suspension by any agency of the Government which would directly affect its performance of the CRADA. Should IC or any of its personnel involved in this CRADA be debarred or suspended during the term of this CRADA, IC will notify Collaborator within thirty (30) days of receipt of final notice.
Appears in 9 contracts
Samples: Cooperative Research and Development Agreement (Curative Biotechnology Inc), Cooperative Research and Development Agreement (Ziopharm Oncology Inc), Cooperative Research and Development Agreement (Edge Therapeutics, Inc.)
Representations of IC. IC hereby represents to Collaborator that:
9.1.1 (a) IC has the requisite power and authority to enter into this CRADA and to perform according to its terms, and that IC’s official signing this CRADA has authority to do so.
9.1.2 (b) To the best of its knowledge and belief, neither IC nor any of its personnel involved in this CRADA is presently subject to debarment or suspension by any agency of the Government which would directly affect its performance of the CRADA. Should IC or any of its personnel involved in this CRADA be debarred or suspended during the term of this CRADA, IC will notify Collaborator within thirty (30) days of receipt of final notice.
Appears in 5 contracts
Samples: Cooperative Research and Development Agreement (BriaCell Therapeutics Corp.), Cooperative Research and Development Agreement (Scopus BioPharma Inc.), Cooperative Research and Development Agreement (Scopus BioPharma Inc.)
Representations of IC. IC hereby represents to Collaborator that:
9.1.1 IC has the requisite power and authority to enter into this CRADA and to perform according to its terms, and that IC’s official signing this CRADA has authority to do so.
9.1.2 To the best of its knowledge and belief, neither IC nor any of its personnel involved in this CRADA is presently subject to debarment or suspension by any agency of the Government which that would directly affect its performance of the CRADA. Should IC or become aware that any of its personnel involved in this CRADA be are debarred or suspended during the term of this CRADA, IC will notify Collaborator within thirty (30) days of receipt of final noticedays.
Appears in 3 contracts
Samples: Cooperative Research and Development Agreement, Cooperative Research and Development Agreement, Cooperative Research and Development Agreement
Representations of IC. IC hereby represents to Collaborator that:
9.1.1 (a) IC has the requisite power and authority to enter into this CRADA and to perform according to its terms, and that IC’s official signing this CRADA has authority to do so.
9.1.2 (b) To the best of its knowledge and belief, neither IC nor any of its personnel involved in this CRADA is presently subject to debarment or suspension by any agency of the Government which would directly affect its performance of the CRADA. Should IC or any of its personnel involved in this CRADA be debarred or suspended during the term of this CRADA, IC will notify Collaborator within thirty (30) days of receipt of final notice.. PHS CRADA Agreement Ref. No. 2020-12 MODEL ADOPTED June 18, 2009 Page 11 of 26 Confidential Revised August 1, 2012
Appears in 1 contract
Samples: Cooperative Research and Development Agreement (Virpax Pharmaceuticals, Inc.)
